[New perspectives for an adjuvant chemotherapy in solid tumors].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Seeber.
Explore the source record for details and available documents.
In a prospective study 18 patients with metastasizing testicular teratomas were treated with adriamycin, bleomycin and vincristin. Sixteen could be fully evaluated: 12 in stage IV (visceral metastases), three in stage III (lymphondular involvement beyond the diaphragm) and one with advanced stage II (iliac, para-aortic and inguinal nodes). None of the patients had previously received chemotherapy. Toxic side-effects were not severe enough to prevent 12 patients from being treated on an outpatient basis. Complete remission occurred in five, with four of them still in remission two, eight, ten and eleven months later. Partial remission (50% decrease in tumour size for at least four weeks) occurred in three, with one still improving. No change was noted for 11 months in a patient with advanced pulmonary disease. Progression under therapy occurred in seven patients and in some of them there was an initial response which did not, however, meet the criteria of partial remission. The therapeutic results as well as toxicity suggest that this regime is superior to actinomycin D montherapy and various previously used combinations.
In a case with leukemic lymphosarcomatosis huge nucleoli developed at a final stage refractory to chemotherapy. The lymphosarcoma cells were characterized before and after their macronucleolar transformation by cell fractionation and by biochemical characterization of their nuclear 45S RNA fraction after high specific labelling with 32P-orthophosphate. The analyses provided evidence for a marked increase in nucleolar 45S RNA production. Processing of preribosomal RNA did not seem to be blocked. The biochemical alterations are discussed especially with respect to a possible significance of biological changes during the development of drug resistance against cytostatic agents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.